This comprehensive Thalassemia Market report underlines the primary and secondary drivers, market share, possible sales volume, leading segments and geographical analysis. Have your business at the highest level of growth with this all-inclusive Thalassemia Market research report. Moreover, this market research report puts forth thorough overview of the market where it identifies industry trends, determines brand awareness and influence, provides industry insights and offers competitive intelligence. The report precisely collects the information about effective factors for the Healthcare industry which includes customer behaviour, emerging trends, product usage, and brand positioning.
Global Thalassemia Market is expected to rise from its initial estimated value of USD 1.99 billion to a projected value of USD 4.36 billion by 2026, registering a CAGR of 10.29% in the forecast period of 2019-2026.
Get Exclusive Sample Report: @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market
Market Definition: Global Thalassemia Market
Thalassemia is a genetic blood disorder which results in indifferent production of hemoglobin in the blood cells of the human body. Hemoglobin is that protein whose function is to carry oxygen throughout the human body which results in the destruction of blood cells leading to humans suffering from anemia.
- Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth
- Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth
- Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth
- High cost of treatment for the disorder is expected to act as a restraint to the market growth
Segmentation: Global Thalassemia Market
- By Thalassemia Type
- Alpha Thalassemia
- Beta Thalassemia
- By Therapeutic Class
- Iron Chelating Drugs
- Exjade/Jadenu (deferasirox)
- By Pipeline
- Gene Therapy
- By End-User
- Research Institutes
Key Developments in the Market:
- In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for “luspatercept” with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases.
- In January 2019, Vifor Pharma announced positive results from their phase-I trial of “VIT-2763” an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state.
Competitive Analysis: Global Thalassemia Market
Global thalassemia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of thalassemia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research